AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2020
Mar 3, 2020
29821_dirs_2020-03-03_5c00dd45-5b09-449a-8fbb-a7d193ce9771.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2020-03-02
Reporting Person: Ballinger Kevin J. (EVP & Pres, Interven Cardio)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-02 | Common Stock | S | 15783.0000 | $37.2059 | Disposed | 80085.0000 | Direct |
Footnotes
F1: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.